Full Text
How Does The Additional Benefit Extent of Orphan Drugs Impact Price Negotiations In The German Outpatient Sector?

Abstract

Authors

M Freiberg R Schwarz F Fath

Back to Volume 18, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×